Mary Chapman, features writer —

Mary graduated from Wayne State University with a degree in journalism. She began her career at United Press International, then spent a decade reporting for the Bureau of National Affairs, Inc. (now Bloomberg Industry Group). Mary has written extensively for The New York Times, and her work has appeared in publications such as Time, Newsweek, Fortune, and the Chicago Tribune. She’s won a Society of Professional Journalists award for outstanding reporting.

Articles by Mary Chapman

ALS Community Invited to Help Set Research Priorities in US

The National Institute of Neurological Disorders and Stroke (NINDS) is asking people across the amyotrophic lateral sclerosis (ALS) community to submit their preferences regarding what should be prioritized to accelerate ALS research. NINDS, which is part of the National Institutes of Health (NIH), is seeking contributions from ALS patients,…

Lief Care and AxeALS Partner to Support Patients’ Nutritional Needs

A Lief Cares initiative, under its partnership with AxeALS, raised nearly $8,000 for the amyotrophic lateral sclerosis (ALS) community and is providing patients with specially formulated nutritional supplements. Lief Cares is the nonprofit donation program of the California-based formulation and product developer and dietary supplement manufacturer Lief Labs. Through…

PRO-ACT Database Wins Healey Center Prize for Innovation in ALS

The largest collection of amyotrophic lateral sclerosis (ALS) clinical trial data, amassed to help researchers globally find better treatments and potentially a cure for the progressive neurological disorder, was awarded the $50,000 Healey Center International Prize for Innovation in ALS. The Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT)…

Landmark ACT for ALS Act on President’s Desk

If signed by President Joe Biden, the bipartisan Accelerating Access to Critical Therapies (ACT) for ALS Act will fund crucial research into fast-progressing neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and provide patients with early access to promising treatment candidates. The legislation (HR 3537), which has passed the…

Home Test in UK Shows How Support Robot Could Help Patients

Before his recent death, motor neuron disease (MND) patient Anthony Walsh had the opportunity to try a prototype Toyota Human Support Robot (HSR), providing a glimpse into the kind of technology that could be used to help people with amyotrophic lateral sclerosis and other MNDs with everyday tasks. Walsh, who was…

United to End MND ‘Disappointed’ by No UK Government Funding

The United to End MND campaign in the United Kingdom is “disappointed” the nation’s government did not accept its plea to invest £50 million (about $68 million) in targeted motor neuron disease (MND) research. MNDs are a group of progressive neurological disorders that includes amyotrophic lateral sclerosis, commonly…

Numotion, Team Gleason Partner to Improve Patient Equipment Access

Numotion has partnered with Team Gleason — the nonprofit started by former pro football player Steve Gleason after his 2011 amyotrophic lateral sclerosis (ALS) diagnosis — to improve access to advanced equipment and technology for ALS patients and their families. The partners also will focus on developing mobility and…

Motor Neurone Disease Association Earns High Praise

The United Kingdom-based Motor Neurone Disease (MND) Association was commended recently at the Third Sector Awards for its efforts in the MND community. The nonprofit organization won high commendations in the “Charity of the Year: Over £5M” category at the annual awards, which recognizes the achievements of charitable organizations and…